NYSEAMERICAN:PFNX - Pfenex Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $5.35 +0.13 (+2.49 %) (As of 07/17/2018 04:00 PM ET)Previous Close$5.22Today's Range$5.17 - $5.6252-Week Range$2.07 - $8.42Volume353,000 shsAverage Volume176,849 shsMarket Capitalization$106.11 millionP/E RatioN/ADividend YieldN/ABeta3.6 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California. Receive PFNX News and Ratings via Email Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSEAMERICAN:PFNX CUSIPN/A Webwww.pfenex.com Phone+1-858-3524400 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-175.52% Return on Equity-63.57% Return on Assets-46.31% Miscellaneous EmployeesN/A Outstanding Shares23,580,000Market Cap$106.11 Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions What is Pfenex's stock symbol? Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX." How were Pfenex's earnings last quarter? Pfenex Inc (NYSEAMERICAN:PFNX) announced its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.04. The biotechnology company earned $3.75 million during the quarter, compared to analyst estimates of $5.52 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. View Pfenex's Earnings History. When is Pfenex's next earnings date? Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Pfenex. What price target have analysts set for PFNX? 3 analysts have issued 12-month price objectives for Pfenex's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Pfenex's stock price to reach $8.00 in the next year. This suggests a possible upside of 49.5% from the stock's current price. View Analyst Ratings for Pfenex. What is the consensus analysts' recommendation for Pfenex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Pfenex? Pfenex saw a increase in short interest in June. As of June 29th, there was short interest totalling 1,399,573 shares, an increase of 784.1% from the June 15th total of 158,308 shares. Based on an average trading volume of 393,704 shares, the days-to-cover ratio is currently 3.6 days. Approximately 4.9% of the company's stock are short sold. View Pfenex's Current Options Chain. Who are some of Pfenex's key competitors? Some companies that are related to Pfenex include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF). Who are Pfenex's key executives? Pfenex's management team includes the folowing people: Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)Dr. Hubert C. Chen, Chief Medical & Scientific Officer (Age 49)Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)Ms. Susan A. Knudson, Chief Financial Officer (Age 54) Has Pfenex been receiving favorable news coverage? News articles about PFNX stock have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfenex earned a coverage optimism score of 0.08 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are Pfenex's major shareholders? Pfenex's stock is owned by many different of institutional and retail investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (10.54%) and Sanders Morris Harris LLC (3.72%). Company insiders that own Pfenex stock include Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex. Which major investors are selling Pfenex stock? PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for Pfenex. How do I buy shares of Pfenex? Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pfenex's stock price today? One share of PFNX stock can currently be purchased for approximately $5.35. How big of a company is Pfenex? Pfenex has a market capitalization of $106.11 million. How can I contact Pfenex? Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400. MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 142 (Vote Outperform)Underperform Votes: 113 (Vote Underperform)Total Votes: 255MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?